Apellis Pharmaceuticals to Present at the BMO 2020 Prescriptions for Success Healthcare ConferenceGlobeNewsWire • 06/16/20
New Pivotal Data Demonstrate Superiority of Apellis’ Pegcetacoplan to Eculizumab in Improving Hemoglobin Levels, Independent of Prior Transfusions, in PNHGlobeNewsWire • 06/12/20
Apellis Pharmaceuticals Announces - Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 05/29/20
Apellis Announces Plans to Submit NDA for Pegcetacoplan in Paroxysmal Nocturnal Hemoglobinuria (PNH)GlobeNewsWire • 05/21/20
Apellis to Present Pivotal Paroxysmal Nocturnal Hemoglobinuria (PNH) Data at 25th EHA Annual CongressGlobeNewsWire • 05/14/20
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 05/07/20
Apellis Pharmaceuticals Announces Private Placement of Convertible Senior NotesGlobeNewsWire • 05/07/20
Apellis Pharmaceuticals - Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 01/16/20
Apellis Pharmaceuticals Phase 3 Success, And Other News: The Good, Bad, And Ugly Of BiopharmaSeeking Alpha • 01/10/20
Apellis Pharmaceuticals: PEGASUS Trial Confirms Pegcetacoplan's Efficacy Over Soliris In PNH PatientsSeeking Alpha • 01/09/20
Apellis' Lead Drug Tops Alexion's Blockbuster Soliris in a Pivotal Late-Stage StudyThe Motley Fool • 01/07/20
This Biotech Just Topped Alexion's Biggest Moneymaker — And RocketedInvestors Business Daily • 01/07/20
Apellis Reports Positive Top-line Results from Phase 3 Head-to-Head Study of Pegcetacoplan (APL-2) Compared to Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)GlobeNewsWire • 01/07/20
Are Options Traders Betting on a Big Move in Apellis Pharmaceuticals (APLS) Stock?Zacks Investment Research • 12/09/19
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).GlobeNewsWire • 11/15/19